{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T02:13:26Z","timestamp":1723083206002},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1007\/s11938-006-0008-5","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T17:14:49Z","timestamp":1180890889000},"page":"520-529","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antiviral therapy for hepatitis C in the setting of liver transplantation"],"prefix":"10.1007","volume":"9","author":[{"given":"Gregory T.","family":"Everson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clark C.","family":"Kulig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"Suppl 2","key":"8_CR1","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1002\/lt.20597","volume":"11","author":"M Charlton","year":"2005","unstructured":"Charlton M: Recurrence of hepatitis C infection: Where are we now?\n                  Liver Transpl 2005, 11(Suppl 2):S57-S62.","journal-title":"Liver Transpl"},{"key":"8_CR2","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/lt.20725","volume":"12","author":"G Ercolani","year":"2006","unstructured":"Ercolani G, Grazi G, Ravaioli M, et al.: Histological recurrent hepatitis C after liver transplantation: outcome and role of retransplantation. Liver Transpl 2006, 12:1104\u20131111.","journal-title":"Liver Transpl"},{"key":"8_CR3","first-page":"61","volume":"50","author":"UP Neumann","year":"2004","unstructured":"Neumann UP, Neuhaus P: Course and treatment of recurrent hepatitis C after liver transplantation. Minerva Gastroenterol Dietol 2004, 50:61\u201366.","journal-title":"Minerva Gastroenterol Dietol"},{"key":"8_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/jlts.2003.50268","volume":"9","author":"RH Wiesner","year":"2003","unstructured":"Wiesner RH, Sorrell M, Villamil F: Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003, 9:S1-S9.","journal-title":"Liver Transpl"},{"key":"8_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/jlts.2002.32282","volume":"8","author":"KW Burak","year":"2002","unstructured":"Burak KW, Kremers WK, Batts KP, et al.: Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002, 8:362\u2013369.","journal-title":"Liver Transpl"},{"key":"8_CR6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.transproceed.2004.12.042","volume":"37","author":"T Kato","year":"2005","unstructured":"Kato T, Yoshida H, Sadfar K, et al.: Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. Transplant Proc 2005, 37:1217\u20131219.","journal-title":"Transplant Proc"},{"key":"8_CR7","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/hep.20119","volume":"39","author":"DB Strader","year":"2004","unstructured":"Strader DB, Wright T, Thomas DL, et al.: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147\u20131171.","journal-title":"Hepatology"},{"key":"8_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0168-8278(03)00310-6","volume":"39","author":"X Forns","year":"2003","unstructured":"Forns X, Garcia-Retortillo M, Serrano T, et al.: Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003, 39:389\u2013396.","journal-title":"J Hepatol"},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/hep.20793","volume":"42","author":"GT Everson","year":"2005","unstructured":"Everson GT, Trotter J, Forman L, et al.: Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42:255\u2013262. Single-center experience notes a 50% SVR in decompensated genotype 2 and 3 HCV-infected patients treated with LADR. SVR was 13% and toxicity was increased in genotype 1 patients.","journal-title":"Hepatology"},{"key":"8_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/jlts.2002.31748","volume":"8","author":"JS Crippin","year":"2002","unstructured":"Crippin JS, McCashland T, Terrault N, et al.: A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002, 8:350\u2013355.","journal-title":"Liver Transpl"},{"key":"8_CR11","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1053\/jlts.2003.50166","volume":"9","author":"RM Thomas","year":"2003","unstructured":"Thomas RM, Brems JJ, Guzman-Hartman G, et al.: Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003, 9:905\u2013915.","journal-title":"Liver Transpl"},{"key":"8_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.cld.2005.05.011","volume":"9","author":"GT Everson","year":"2005","unstructured":"Everson GT: Treatment of hepatitis C in patients who have decompensated cirrhosis. Clin Liver Dis 2005, 9:473\u2013486.","journal-title":"Clin Liver Dis"},{"key":"8_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/hep.20345","volume":"40","author":"X Forns","year":"2004","unstructured":"Forns X, Navasa M, Rodes J: Treatment of HCV infection in patients with advanced cirrhosis. Hepatology 2004, 40:498.","journal-title":"Hepatology"},{"key":"8_CR14","unstructured":"National Institutes of Health. Low accelerating dosage regimen (LADR) ancillary study of the adult to adult living donor liver transplantation study (A2ALL). Available at: www.nih-a2all.org. Accessed June 15, 2006."},{"key":"8_CR15","unstructured":"Hepatitis C long-term treatment against cirrhosis study (HALT-C). Available at: www.haltctrial.org. Accessed June 15, 2006."},{"key":"8_CR16","unstructured":"Study of long-term peg intron vs. colchicine in nonresponders (COPILOT). Available at: www.clinicaltrials. gov\/ct\/show\/NCT00179413. Accessed June 23, 2006."},{"key":"8_CR17","first-page":"238A","volume":"40","author":"NH Afdhal","year":"2004","unstructured":"Afdhal NH, Freilich B, Levine R. Colchicine versus pegintron long-term (COPILOT) trial: interim analysis of clinical outcomes at year 2 [abstract]. Hepatology 2004, 40:238A.","journal-title":"Hepatology"},{"key":"8_CR18","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/lt.20405","volume":"11","author":"GL Davis","year":"2005","unstructured":"Davis GL, Nelson DR, Terrault N, et al.: A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005, 11:941\u2013949.","journal-title":"Liver Transpl"},{"key":"8_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.20560","volume":"41","author":"N Chalasani","year":"2005","unstructured":"Chalasani N, Manzarbeitia C, Ferenci P, et al.: Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005, 41:289\u2013298.","journal-title":"Hepatology"},{"key":"8_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1600-6143.2004.00648.x","volume":"5","author":"AK Shergill","year":"2005","unstructured":"Shergill AK, Khalili M, Straley S, et al.: Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005, 5:118\u2013124. Sole randomized trial of preemptive combination therapy. SVR was 18.0% with RBV, 2.5% without.","journal-title":"Am J Transplant"},{"key":"8_CR21","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1097\/01.TP.0000142677.12473.E5","volume":"78","author":"Y Sugawara","year":"2004","unstructured":"Sugawara Y, Makuuchi M, Matsui Y, et al.: Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004, 78:1308\u20131311.","journal-title":"Transplantation"},{"key":"8_CR22","unstructured":"A study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (ribavirin) administered after liver transplantation for hepatitis C (PHOENIX). Available at: www.clinicaltrials.gov\/ct\/gui\/show\/NCT00087633. Accessed June 15, 2006."},{"key":"8_CR23","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1053\/gast.2003.50095","volume":"124","author":"D Samuel","year":"2003","unstructured":"Samuel D, Bizollon T, Feray C, et al.: Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003, 124:642\u2013650. The sole randomized trial of combination therapy in the setting of histologically evident post-transplantation HCV recurrence. EOTR and SVR rates were 32% and 21%, respectively, in the treatment group, with lack of EOTR and SVR in controls who received no antiviral therapy.","journal-title":"Gastroenterology"},{"key":"8_CR24","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1053\/jlts.2002.34968","volume":"8","author":"RJ Firpi","year":"2002","unstructured":"Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al.: Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002, 8:1000\u20131006.","journal-title":"Liver Transpl"},{"key":"8_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1136\/gut.52.2.283","volume":"52","author":"T Bizollon","year":"2003","unstructured":"Bizollon T, Ahmed SN, Radenne S, et al.: Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003, 52:283\u2013287.","journal-title":"Gut"},{"key":"8_CR26","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1097\/00042737-200411000-00020","volume":"16","author":"M Berenguer","year":"2004","unstructured":"Berenguer M, Prieto M, Palau A, et al.: Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol 2004, 16:1207\u20131212.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"8_CR27","first-page":"169","volume":"17","author":"E Giostra","year":"2004","unstructured":"Giostra E, Kullak-Ublick GA, Keller W, et al.: Ribavirin\/ interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 2004, 17:169\u2013176.","journal-title":"Transpl Int"},{"key":"8_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1400-1746.2004.03483.x","volume":"20","author":"S Mukherjee","year":"2005","unstructured":"Mukherjee S, Lyden E, McCashland TM, Schafer DF: Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients. J Gastroenterol Hepatol 2005, 20:198\u2013203.","journal-title":"J Gastroenterol Hepatol"},{"key":"8_CR29","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.transproceed.2006.02.135","volume":"38","author":"P Burra","year":"2006","unstructured":"Burra P, Targhetta S, Pevere S, et al.: Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience. Transplant Proc 2006, 38:1127\u20131130.","journal-title":"Transplant Proc"},{"key":"8_CR30","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1053\/jlts.2002.33968","volume":"8","author":"KV Narayanan Menon","year":"2002","unstructured":"Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al.: Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002, 8:623\u2013629.","journal-title":"Liver Transpl"},{"key":"8_CR31","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jhep.2003.12.015","volume":"40","author":"J Dumortier","year":"2004","unstructured":"Dumortier J, Scoazec JY, Chevallier P, Boillot O: Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004, 40:669\u2013674.","journal-title":"J Hepatol"},{"key":"8_CR32","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/01.TP.0000129811.93072.1C","volume":"78","author":"GW Neff","year":"2004","unstructured":"Neff GW, Montalbano M, O\u2019Brien CB, et al.: Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004, 78:1303\u20131307.","journal-title":"Transplantation"},{"key":"8_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/01.TP.0000100481.14514.BB","volume":"77","author":"H Rodriguez-Luna","year":"2004","unstructured":"Rodriguez-Luna H, Khatib A, Sharma P, et al.: Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004, 77:190\u2013194.","journal-title":"Transplantation"},{"key":"8_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jhep.2005.02.015","volume":"43","author":"L Castells","year":"2005","unstructured":"Castells L, Vargas V, Allende H, et al.: Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005, 43:53\u201359.","journal-title":"J Hepatol"},{"key":"8_CR35","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/j.1600-6143.2006.01255.x","volume":"6","author":"M Heydtmann","year":"2006","unstructured":"Heydtmann M, Freshwater D, Dudley T, et al.: Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. Am J Transplant 2006, 6:825\u2013833.","journal-title":"Am J Transplant"},{"key":"8_CR36","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/01.TP.0000149499.78996.B3","volume":"79","author":"T Bizollon","year":"2005","unstructured":"Bizollon T, Adham M, Pradat P, et al.: Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C. Transplantation 2005, 79:325\u2013329.","journal-title":"Transplantation"},{"key":"8_CR37","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/S0041-1345(03)00458-5","volume":"35","author":"GA Smallwood","year":"2003","unstructured":"Smallwood GA, Davis L, Connor K, et al.: Nonresponders of interferon\/ribavirin treatment for recurrent hepatitis C following liver transplantation. Transplant Proc 2003, 35:1476\u20131477.","journal-title":"Transplant Proc"},{"key":"8_CR38","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/lt.20737","volume":"12","author":"M Berenguer","year":"2006","unstructured":"Berenguer M, Prieto M, Palau A, et al.: Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006, 12:1067\u20131076.","journal-title":"Liver Transpl"},{"key":"8_CR39","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1002\/lt.20517","volume":"11","author":"M Carmiel-Haggai","year":"2005","unstructured":"Carmiel-Haggai M, Fiel MI, Gaddipati HC, et al.: Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl 2005, 11:1567\u20131573.","journal-title":"Liver Transpl"},{"key":"8_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/gut.2005.069674","volume":"55","author":"MJ Walsh","year":"2006","unstructured":"Walsh MJ, Jonsson JR, Richardson MM, et al.: Nonresponse to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006, 55:529\u2013535.","journal-title":"Gut"},{"key":"8_CR41","unstructured":"Individualized dosing efficacy vs. flat dosing to assess optimal pegylated interferon therapy (Ideal Study). Available at: www.idealstudy.com. Accessed June 15, 2006."},{"key":"8_CR42","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.cld.2005.05.012","volume":"9","author":"MP Curry","year":"2005","unstructured":"Curry MP, Afdhal NH: Use of growth factors with antiviral therapy for chronic hepatitis C. Clin Liver Dis 2005, 9:439\u2013451.","journal-title":"Clin Liver Dis"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-006-0008-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11938-006-0008-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-006-0008-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-006-0008-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:14:36Z","timestamp":1659093276000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11938-006-0008-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["8"],"URL":"https:\/\/doi.org\/10.1007\/s11938-006-0008-5","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}